Similar articles

• [Distribution of orphan drugs by the pharmacist of the Faculty of Veterinary Medicine].

  [No authors listed] [No authors listed] Tijdschr Diergeneeskd. 2004 Jul 15-Aug 1;129(14-15):486. Tijdschr Diergeneeskd. 2004. PMID: 15344826 Dutch. No abstract available.
• Rare diseases, orphan drugs, and orphaned patients.

  Scheindlin S. Scheindlin S. Mol Interv. 2006 Aug;6(4):186-91. doi: 10.1124/mi.6.4.2. Mol Interv. 2006. PMID: 16960139 No abstract available.
• The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.

  Burke KA, Freeman SN, Imoisili MA, Coté TR. Burke KA, et al. Clin Pharmacol Ther. 2010 Oct;88(4):449-53. doi: 10.1038/clpt.2010.193. Clin Pharmacol Ther. 2010. PMID: 20856241 Review.
• The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?

  Wellman-Labadie O, Zhou Y. Wellman-Labadie O, et al. Health Policy. 2010 May;95(2-3):216-28. doi: 10.1016/j.healthpol.2009.12.001. Epub 2009 Dec 29. Health Policy. 2010. PMID: 20036435
• Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.

  Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM. Heemstra HE, et al. Drug Discov Today. 2011 Jan;16(1-2):73-80. doi: 10.1016/j.drudis.2010.11.006. Epub 2010 Nov 20. Drug Discov Today. 2011. PMID: 21094692 Review.